3% of MS Sherpa users were able to safely stop their medication altogether.

Another week, another impact update. This time, we're highlighting a solution regarding a disease that affects around 36,000 people in the Netherlands. Our portfolio company MS Sherpa  is changing the way people with MS experience care, and the impact is measurable. 🙌

Living with MS means living with uncertainty. Neurologists typically see patients only a few times a year, leaving long periods in which symptoms can change without their clinician knowing. As a result, patients may remain on medication that is no longer effective or continue treatment they could safely stop.

MS Sherpa enables patients to monitor their condition more frequently between appointments. Through a clinician dashboard, neurologists receive continuous insights that support better, more personalised treatment decisions without having to wait for the next consultation.

In 2025, 3% of MS Sherpa users were able to safely stop their medication altogether. For someone living with MS, that is more than a statistic. It can be life changing.

𝗧𝗵𝗲 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗶𝘀 𝗻𝗼𝘄 𝗮𝗰𝘁𝗶𝘃𝗲 𝗶𝗻 𝟵 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹𝘀, 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝟵𝟱𝟱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝗮𝗻𝗱 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗲𝗱 €𝟯𝟬𝟬𝗸 𝗶𝗻 𝗮𝘃𝗼𝗶𝗱𝗮𝗯𝗹𝗲 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝘀𝘁𝘀 𝗶𝗻 𝟮𝟬𝟮𝟱.

Stopping MS medication is never a decision taken lightly. The fact that 3% of patients could do so safely, supported by better data and closer monitoring, demonstrates what smarter digital care can achieve.

This is exactly the kind of innovation we invest in: technology that helps people receive better care while making healthcare more sustainable.

MS Sherpa is one example of the impact our portfolio is creating. Our Impact in Progress 2025 report highlights the results of ten portfolio companies.

𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝘁𝗵𝗲𝘆 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗲𝗱 €𝟴𝟴.𝟯 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗰𝗼𝘀𝘁𝘀 𝗶𝗻 𝟮𝟬𝟮𝟱, 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗼𝘃𝗲𝗿 𝟭 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗹𝗶𝘃𝗲𝘀, 𝗮𝗻𝗱 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱 €𝟱 𝗶𝗻 𝘀𝗼𝗰𝗶𝗲𝘁𝗮𝗹 𝘃𝗮𝗹𝘂𝗲 𝗳𝗼𝗿 𝗲𝘃𝗲𝗿𝘆 €𝟭 𝘄𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗲𝗱.

Read the public version down below⤵️). For questions, send Douwe Jippes, Alexander van der Wyck, Karen Berg or Thom Nefkens a personal message.

‍